ginsenoside rh2  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    MedChemExpress ginsenoside rh2
    KIF26B modulates SRF m6A methylation in cancer cells. A. Potential m6A modification sites in the sequence of SRF mRNA (NM_003131.3). B–C. Gene-specific m6A RIP-qPCR assay showing the reduction of m6A modification in specific regions of SRF mRNA by shKIF26B in MDA-MB-157 (B) and NMFH-1 (C) cells. D-F. SRF mRNA (D-E) and protein (F) expression in MDA-MB-157 and NMFH-1 cells with lentiviral mediated KIF26B knockdown. G-H. SRF mRNA expression in MDA-MB-157 (G) and NMFH-1 (H) cells at the indicated time points after actinomycin D treatment. I. A potential positive feedback loop between KIF26B and SRF in cancer cells and the regulatory effect of <t>ginsenoside</t> <t>Rh2</t> on m6A RNA methylation via KIF26B. ∗, Scramble vs. shKIF26B#1; #, Scramble vs. shKIF26B#2; ## and ∗∗, p
    Ginsenoside Rh2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ginsenoside rh2/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ginsenoside rh2 - by Bioz Stars, 2022-05
    93/100 stars

    Images

    1) Product Images from "Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop"

    Article Title: Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop

    Journal: Journal of Ginseng Research

    doi: 10.1016/j.jgr.2021.05.004

    KIF26B modulates SRF m6A methylation in cancer cells. A. Potential m6A modification sites in the sequence of SRF mRNA (NM_003131.3). B–C. Gene-specific m6A RIP-qPCR assay showing the reduction of m6A modification in specific regions of SRF mRNA by shKIF26B in MDA-MB-157 (B) and NMFH-1 (C) cells. D-F. SRF mRNA (D-E) and protein (F) expression in MDA-MB-157 and NMFH-1 cells with lentiviral mediated KIF26B knockdown. G-H. SRF mRNA expression in MDA-MB-157 (G) and NMFH-1 (H) cells at the indicated time points after actinomycin D treatment. I. A potential positive feedback loop between KIF26B and SRF in cancer cells and the regulatory effect of ginsenoside Rh2 on m6A RNA methylation via KIF26B. ∗, Scramble vs. shKIF26B#1; #, Scramble vs. shKIF26B#2; ## and ∗∗, p
    Figure Legend Snippet: KIF26B modulates SRF m6A methylation in cancer cells. A. Potential m6A modification sites in the sequence of SRF mRNA (NM_003131.3). B–C. Gene-specific m6A RIP-qPCR assay showing the reduction of m6A modification in specific regions of SRF mRNA by shKIF26B in MDA-MB-157 (B) and NMFH-1 (C) cells. D-F. SRF mRNA (D-E) and protein (F) expression in MDA-MB-157 and NMFH-1 cells with lentiviral mediated KIF26B knockdown. G-H. SRF mRNA expression in MDA-MB-157 (G) and NMFH-1 (H) cells at the indicated time points after actinomycin D treatment. I. A potential positive feedback loop between KIF26B and SRF in cancer cells and the regulatory effect of ginsenoside Rh2 on m6A RNA methylation via KIF26B. ∗, Scramble vs. shKIF26B#1; #, Scramble vs. shKIF26B#2; ## and ∗∗, p

    Techniques Used: Methylation, Modification, Sequencing, Real-time Polymerase Chain Reaction, Multiple Displacement Amplification, Expressing

    Ginsenoside Rh2 reduces m6A RNA methylation and KIF26B expression in some cancers. A. mRNA m6A content in ginsenoside Rh2 treated (10 or 20 nM, 24 h) cancer cell lines. B. KIF26B mRNA expression in multiple cancer cell lines (the same as in panel A) after treatment with ginsenoside Rh2 (20 nM, 24 h). C-D. Basal KIF26B protein expression in cancer cell lines as in panel A (C) and in three selected cancer cell lines (MDA-MB-157, NMFH-1, and TT) after treatment with ginsenoside Rh2 (20 nM, 24 h) (D). E-F. KIF26B mRNA (top panel) and protein (bottom panel) expression in MDA-MB-157 (E) and NMFH-1 (F) cells with lentiviral mediated KIF26B knockdown, or in combination with lentiviral KIF26B expression vector resistant to shKIF26B#1 (MT-KIF26B). G-J. mRNA m6A content in KIF26B knockdown alone or control MDA-MB-157 (G) and NMFH-1 (H) cells, and in MDA-MB-157 (I) and NMFH-1 (J) cells with ginsenoside Rh2 treatment alone (20 nM, 24 h) or in combination with WT-KIF26B overexpression.
    Figure Legend Snippet: Ginsenoside Rh2 reduces m6A RNA methylation and KIF26B expression in some cancers. A. mRNA m6A content in ginsenoside Rh2 treated (10 or 20 nM, 24 h) cancer cell lines. B. KIF26B mRNA expression in multiple cancer cell lines (the same as in panel A) after treatment with ginsenoside Rh2 (20 nM, 24 h). C-D. Basal KIF26B protein expression in cancer cell lines as in panel A (C) and in three selected cancer cell lines (MDA-MB-157, NMFH-1, and TT) after treatment with ginsenoside Rh2 (20 nM, 24 h) (D). E-F. KIF26B mRNA (top panel) and protein (bottom panel) expression in MDA-MB-157 (E) and NMFH-1 (F) cells with lentiviral mediated KIF26B knockdown, or in combination with lentiviral KIF26B expression vector resistant to shKIF26B#1 (MT-KIF26B). G-J. mRNA m6A content in KIF26B knockdown alone or control MDA-MB-157 (G) and NMFH-1 (H) cells, and in MDA-MB-157 (I) and NMFH-1 (J) cells with ginsenoside Rh2 treatment alone (20 nM, 24 h) or in combination with WT-KIF26B overexpression.

    Techniques Used: Methylation, Expressing, Multiple Displacement Amplification, Plasmid Preparation, Over Expression

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    MedChemExpress ginsenoside rh2
    KIF26B modulates SRF m6A methylation in cancer cells. A. Potential m6A modification sites in the sequence of SRF mRNA (NM_003131.3). B–C. Gene-specific m6A RIP-qPCR assay showing the reduction of m6A modification in specific regions of SRF mRNA by shKIF26B in MDA-MB-157 (B) and NMFH-1 (C) cells. D-F. SRF mRNA (D-E) and protein (F) expression in MDA-MB-157 and NMFH-1 cells with lentiviral mediated KIF26B knockdown. G-H. SRF mRNA expression in MDA-MB-157 (G) and NMFH-1 (H) cells at the indicated time points after actinomycin D treatment. I. A potential positive feedback loop between KIF26B and SRF in cancer cells and the regulatory effect of <t>ginsenoside</t> <t>Rh2</t> on m6A RNA methylation via KIF26B. ∗, Scramble vs. shKIF26B#1; #, Scramble vs. shKIF26B#2; ## and ∗∗, p
    Ginsenoside Rh2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ginsenoside rh2/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    ginsenoside rh2 - by Bioz Stars, 2022-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    KIF26B modulates SRF m6A methylation in cancer cells. A. Potential m6A modification sites in the sequence of SRF mRNA (NM_003131.3). B–C. Gene-specific m6A RIP-qPCR assay showing the reduction of m6A modification in specific regions of SRF mRNA by shKIF26B in MDA-MB-157 (B) and NMFH-1 (C) cells. D-F. SRF mRNA (D-E) and protein (F) expression in MDA-MB-157 and NMFH-1 cells with lentiviral mediated KIF26B knockdown. G-H. SRF mRNA expression in MDA-MB-157 (G) and NMFH-1 (H) cells at the indicated time points after actinomycin D treatment. I. A potential positive feedback loop between KIF26B and SRF in cancer cells and the regulatory effect of ginsenoside Rh2 on m6A RNA methylation via KIF26B. ∗, Scramble vs. shKIF26B#1; #, Scramble vs. shKIF26B#2; ## and ∗∗, p

    Journal: Journal of Ginseng Research

    Article Title: Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop

    doi: 10.1016/j.jgr.2021.05.004

    Figure Lengend Snippet: KIF26B modulates SRF m6A methylation in cancer cells. A. Potential m6A modification sites in the sequence of SRF mRNA (NM_003131.3). B–C. Gene-specific m6A RIP-qPCR assay showing the reduction of m6A modification in specific regions of SRF mRNA by shKIF26B in MDA-MB-157 (B) and NMFH-1 (C) cells. D-F. SRF mRNA (D-E) and protein (F) expression in MDA-MB-157 and NMFH-1 cells with lentiviral mediated KIF26B knockdown. G-H. SRF mRNA expression in MDA-MB-157 (G) and NMFH-1 (H) cells at the indicated time points after actinomycin D treatment. I. A potential positive feedback loop between KIF26B and SRF in cancer cells and the regulatory effect of ginsenoside Rh2 on m6A RNA methylation via KIF26B. ∗, Scramble vs. shKIF26B#1; #, Scramble vs. shKIF26B#2; ## and ∗∗, p

    Article Snippet: Ginsenoside Rh2 was purchased from MedChemExpress (Purity≥98%, Shanghai, China).

    Techniques: Methylation, Modification, Sequencing, Real-time Polymerase Chain Reaction, Multiple Displacement Amplification, Expressing

    Ginsenoside Rh2 reduces m6A RNA methylation and KIF26B expression in some cancers. A. mRNA m6A content in ginsenoside Rh2 treated (10 or 20 nM, 24 h) cancer cell lines. B. KIF26B mRNA expression in multiple cancer cell lines (the same as in panel A) after treatment with ginsenoside Rh2 (20 nM, 24 h). C-D. Basal KIF26B protein expression in cancer cell lines as in panel A (C) and in three selected cancer cell lines (MDA-MB-157, NMFH-1, and TT) after treatment with ginsenoside Rh2 (20 nM, 24 h) (D). E-F. KIF26B mRNA (top panel) and protein (bottom panel) expression in MDA-MB-157 (E) and NMFH-1 (F) cells with lentiviral mediated KIF26B knockdown, or in combination with lentiviral KIF26B expression vector resistant to shKIF26B#1 (MT-KIF26B). G-J. mRNA m6A content in KIF26B knockdown alone or control MDA-MB-157 (G) and NMFH-1 (H) cells, and in MDA-MB-157 (I) and NMFH-1 (J) cells with ginsenoside Rh2 treatment alone (20 nM, 24 h) or in combination with WT-KIF26B overexpression.

    Journal: Journal of Ginseng Research

    Article Title: Ginsenoside Rh2 reduces m6A RNA methylation in cancer via the KIF26B-SRF positive feedback loop

    doi: 10.1016/j.jgr.2021.05.004

    Figure Lengend Snippet: Ginsenoside Rh2 reduces m6A RNA methylation and KIF26B expression in some cancers. A. mRNA m6A content in ginsenoside Rh2 treated (10 or 20 nM, 24 h) cancer cell lines. B. KIF26B mRNA expression in multiple cancer cell lines (the same as in panel A) after treatment with ginsenoside Rh2 (20 nM, 24 h). C-D. Basal KIF26B protein expression in cancer cell lines as in panel A (C) and in three selected cancer cell lines (MDA-MB-157, NMFH-1, and TT) after treatment with ginsenoside Rh2 (20 nM, 24 h) (D). E-F. KIF26B mRNA (top panel) and protein (bottom panel) expression in MDA-MB-157 (E) and NMFH-1 (F) cells with lentiviral mediated KIF26B knockdown, or in combination with lentiviral KIF26B expression vector resistant to shKIF26B#1 (MT-KIF26B). G-J. mRNA m6A content in KIF26B knockdown alone or control MDA-MB-157 (G) and NMFH-1 (H) cells, and in MDA-MB-157 (I) and NMFH-1 (J) cells with ginsenoside Rh2 treatment alone (20 nM, 24 h) or in combination with WT-KIF26B overexpression.

    Article Snippet: Ginsenoside Rh2 was purchased from MedChemExpress (Purity≥98%, Shanghai, China).

    Techniques: Methylation, Expressing, Multiple Displacement Amplification, Plasmid Preparation, Over Expression